Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of HS-20093 versus topotecan in relapsed small cell lung cancer
CTR20242440Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risvutatug rezetecan, topotecan in small cell lung cancer (SCLC), sponsored by Hansoh Pharmaceutical Group. Started Jul 2024; status: active.
02
Drugs
risvutatug rezetecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20242440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242440.